Here are the 10-K annual reports from Intelligent Bio Solutions Inc. (INBS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INBS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBS filings page.
Intelligent Bio Solutions Inc. amended its fiscal 2026 annual report to revise executive-compensation and related-party disclosures and correct duplicate or superseded exhibit-index entries. It adds transaction details for Alyeska Master Fund, L.P., a beneficial owner of more than 5%: approximately $831,368 in gross proceeds from the 2025 warrant inducement transaction and approximately $5.0 million from the December private placement. During fiscal 2026, Alyeska exercised warrants for 216,247 common shares for an aggregate exercise price of $118,109.
For awards approved March 18, 2026, Harry Simeonidis, chief executive officer and president, and Spiro Sakiris, chief financial officer, were each awarded 9,150 time-vesting restricted shares and 21,350 performance-vesting restricted shares. The performance awards vest in tranches tied to a clinical-trial milestone, an FDA submission, and a commercial supply and sales milestone, subject to continued service and the stated vesting conditions.
Intelligent Bio Solutions Inc. (INBS) is a Delaware-based medical technology company focused on rapid, non-invasive testing, led by its Intelligent Fingerprinting Platform. The IFP System is a fingerprint sweat-based drug screening solution, commercially available in certain non-U.S. markets, serving over 502 mainly U.K. customers in safety-critical industries.
INBS is pursuing FDA 510(k) clearance for its opiate test to enter the U.S. and is expanding across Europe and the APAC region while operating an ISO 13485/9001-certified manufacturing facility in Cambridge, U.K. A 1-for-10 reverse stock split became effective December 15, 2025. As of June 30, 2026, cash and cash equivalents were $3,992,312, and the company reported net losses of $10,568,733 in 2025 and $12,430,975 in 2026. Management and the auditor highlight substantial doubt about INBS’s ability to continue as a going concern without additional capital, and the company discloses risks around future financings, supply concentration, regulatory approvals, and continued Nasdaq listing compliance.
Intelligent Bio Solutions Inc. (INBS) reported operating results and disclosures in its Form 10-K showing continued commercial rollout of its Intelligent Fingerprinting (IFP) products and persistent losses that raise near-term financing risk. The company installed over 1,000 IFP readers, added 115 new customer accounts, launched localized websites in Arabic, Italian and Spanish, was granted a U.S. patent for its drug screening cartridge, and completed a pharmacokinetic study supporting a 510(k) submission (Dec 2024) for codeine detection.
Financially, revenue line items include reader sales of $711,737 (FY2025) with GAAP gross profit of $1,246,859. The company recorded a net loss of $10,604,886, shareholders' equity of $2,813,824, a working capital deficit of $1,212,419, and an accumulated deficit of $62,533,065. Management discloses an explanatory audit paragraph on its ability to continue as a going concern and states it will need to raise additional capital within twelve months.